Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.22.1
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 30, 2015
May 11, 2015
Jun. 30, 2019
May 31, 2016
Mar. 31, 2015
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Non-Refundable Milestone Payment               $ 4,000,000.0
Commercial Sales In Specified Territories | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           $ 21,500,000    
Neupharma                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payment of upfront licensing fees         $ 1,000,000.0      
Neupharma | Additional Sales Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           40,000,000.0    
Neupharma | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           40,000,000.0    
Neupharma | Regulatory Approvals To Commercialize The Products                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           22,500,000    
Dana-Farber                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Number of shares of common stock granted 136,830 500,000            
Ownership percentage   5.00%            
Cash in exchange for common shares   $ 10,000,000            
Maintenance fee           50,000    
Value of common stock shares issued $ 600,000 $ 32,500            
Sale price per share   $ 0.065            
Dana-Farber | First Commercial Sale Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           21,500,000    
Dana-Farber | Additional Sales Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           60,000,000.0    
Jubilant Biosys Ltd                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payment of upfront licensing fees       $ 2,000,000.0        
Revenue recognition milestone revenue recognized           $ 21,000 $ 23,000  
Proceeds from upfront fees       $ 1,000,000.0        
Research and development cost           50.00%    
Jubilant Biosys Ltd | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           $ 89,000,000.0    
Jubilant Biosys Ltd | Regulatory Approvals To Commercialize The Products                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           59,500,000    
Jubilant Biosys Ltd | Five Regulatory Approvals And First Commercial Sales                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           61,700,000    
Jubilant Biosys Ltd | Sale Millstone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           89,000,000.0    
Maximum potential milestone payments           89,000,000.0    
Jubilant Biosys Ltd | Clinical Development and Regulatory Milestones                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           87,200,000    
Adimab LLC | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Non-Refundable Milestone Payment               $ 2,400,000
Adimab LLC | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           7,100,000    
Adimab LLC | Regulatory Approvals To Commercialize The Products                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           4,800,000    
Collaboration Agreement With TGTX                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone revenue recognized           31,000 $ 45,000  
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000      
Collaboration Agreement With TGTX | First Commercial Sale Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           14,500,000    
Collaboration Agreement With TGTX | First Commercial Sale Milestone | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           27,600,000    
Collaboration Agreement With TGTX | Clinical and Development Milestone | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           7,000,000.0    
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           19,200,000    
Collaboration Agreement With TGTX | Clinical Development and Regulatory Milestones | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           8,400,000    
Sublicense Agreement with TGTX | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           $ 25,500,000